Physiology-based pharmacokinetic modeling suggests that rifabutin can out-balance P-glycoprotein (P-gp) induction by concurrent P-gp inhibition. However, clinical or experimental evidence for this Janus-faced rifabutin effect is missing. Consequently, LS180 cells were exposed to a moderately (2 µM) and strongly (10 µM) P-gp-inducing concentration of rifampicin or rifabutin for 6 days. Cellular accumulation of the fluorescent P-gp substrate rhodamine 123 was evaluated using flow cytometry, either without (induction only) or with adding rifamycin drug to the cells during the rhodamine 123 efflux phase (induction + potential inhibition). Rhodamine 123 accumulation was decreased similarly by both drugs after 6-day exposure (2 µM: 55% residual fluorescence compared to non-induced cells, P < 0.01; 10 µM: 30% residual fluorescence compared to non-induced cells, P < 0.001), indicating P-gp induction. Rhodamine 123 influx transporters mRNA expressions were not affected, excluding off-target effects. Acute re-exposure to rifabutin, however, considerably re-increased rhodamine 123 accumulation (2 µM induction: re-increase by 55%, P < 0.01; 10 µM induction: 49% re-increase, P < 0.001), suggesting P-gp inhibition. In contrast, rifampicin only had weak effects (2 µM induction: no re-increase; 10 µM induction: 16% re-increase; P < 0.05). Molecular docking analysis eventually revealed that rifabutin has a higher binding affinity to the inhibitor binding site of P-gp than rifampicin (ΔG (kcal/mol) = -11.5 vs -5.3). Together, this study demonstrates that rifabutin can at least partly mask P-gp induction by P-gp inhibition, mediated by high affinity binding to the inhibitory site of P-gp.

Boehringer Ingelheim Pharma GmbH and Co KG Birkendorfer Str 65 88397 Biberach an der Riss Germany

Department of Clinical Pharmacology and Pharmacoepidemiology Heidelberg University Hospital Im Neuenheimer Feld 410 69120 Heidelberg Germany

Department of Pharmacology and Toxicology Faculty of Pharmacy Charles University Prague Heyrovskeho 1203 50005 Hradec Kralove Czech Republic

See more in PubMed

Alam A, Küng R, Kowal J, McLeod RA, Tremp N, Broude EV, Roninson IB, Stahlberg H, Locher KP. Structure of a zosuquidar and UIC2-bound human-mouse chimeric ABCB1. Proc Natl Acad Sci U S A. 2018;115:E1973–E1982. doi: 10.1073/pnas.1717044115. PubMed DOI PMC

Alam A, Kowal J, Broude E, Roninson I, Locher KP. Structural insight into substrate and inhibitor discrimination by human P-glycoprotein. Science. 2019;363:753–756. doi: 10.1126/science.aav7102. PubMed DOI PMC

Albermann N, Schmitz-Winnenthal FH, Z’graggen K, Volk C, Hoffmann MM, Haefeli WE, Weiss J. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol. 2005;70:949–958. doi: 10.1016/j.bcp.2005.06.018. PubMed DOI

Amor D, Goutal S, Marie S, Caillé F, Bauer M, Langer O, Auvity S, Tournier N. Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats. EJNMMI Res. 2018;8:81. doi: 10.1186/s13550-018-0434-0. PubMed DOI PMC

Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin and rifabutin drug interactions. Am J Med Sci. 2008;335:126–136. doi: 10.1097/MAJ.0b013e31814a586a. PubMed DOI

Brožová ZR, Dušek J, Palša N, Maixnerová J, Kamaraj R, Smutná L, Matouš P, Braeuning A, Pávek P, Kuneš J, Gathergood N, Špulák M, Pour M, Carazo A. 2-Substituted quinazolines: partial agonistic and antagonistic ligands of the constitutive androstane receptor (CAR) Eur J Med Chem. 2023;259:115631. doi: 10.1016/j.ejmech.2023.115631. PubMed DOI

Dantzig AH, Law KL, Cao J, Starling JJ. Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic. Curr Med Chem. 2001;8:39–50. doi: 10.2174/0929867013373903. PubMed DOI

European Medicines Agency (2023) ICH guideline M12 on drug interaction studies. https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-m12-drug-interaction-studies-step-2b_en.pdf. Accessed on 6 July 2023

Ferreira RJ, Ferreira MJ, dos Santos DJ. Molecular docking characterizes substrate-binding sites and efflux modulation mechanisms within P-glycoprotein. J Chem Inf Model. 2013;53:1747–1760. doi: 10.1021/ci400195v. PubMed DOI

Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampin and rifabutin drug interactions: an update. Arch Intern Med. 2002;162:985–992. doi: 10.1001/archinte.162.9.985. PubMed DOI

Forster S, Thumser AE, Hood SR, Plant N. Characterization of rhodamine-123 as a tracer dye for use in in vitro drug transport assays. PLoS ONE. 2012;7:e33253. doi: 10.1371/journal.pone.0033253. PubMed DOI PMC

Franke RM, Scherkenbach LA, Sparreboom A. Pharmacogenetics of the organic anion transporting polypeptide 1A2. Pharmacogenomics. 2009;10:339–344. doi: 10.2217/14622416.10.3.339. PubMed DOI PMC

Gupta A, Mugundu GM, Desai PB, Thummel KE, Unadkat JD. Intestinal human colon adenocarcinoma cell line LS180 Is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors. Drug Metab Dispos. 2008;36:1172–1180. doi: 10.1124/dmd.107.018689. PubMed DOI

Jouan E, Le Vee M, Denizot C, Da Violante G, Fardel O. The mitochondrial fluorescent dye rhodamine 123 is a high-affinity substrate for organic cation transporters (OCTs) 1 and 2. Fundam Clin Pharmacol. 2014;28:65–77. doi: 10.1111/j.1472-8206.2012.01071.x. PubMed DOI

König SK, Herzog M, Theile D, Zembruski N, Haefeli WE, Weiss J. Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother. 2010;65:2319–2328. doi: 10.1093/jac/dkq324. PubMed DOI

Kusuhara H, Miura M, Yasui-Furukori N, Yoshida K, Akamine Y, Yokochi M, Fukizawa S, Ikejiri K, Kanamitsu K, Uno T, Sugiyama Y. Effect of coadministration of single and multiple doses of rifampicin on the pharmacokinetics of fexofenadine enantiomers in healthy subjects. Drug Metab Dispos. 2013;41:206–213. doi: 10.1124/dmd.112.048330. PubMed DOI

Lutz JD, Kirby BJ, Wang L, Song Q, Ling J, Massetto B, Worth A, Kearney BP, Mathias A. Cytochrome P450 3A induction predicts P-glycoprotein induction; part 1: establishing induction relationships using ascending dose rifampin. Clin Pharmacol Ther. 2018;104:1182–1190. doi: 10.1002/cpt.1073. PubMed DOI PMC

Lutz JD, Kirby BJ, Wang L, Song Q, Ling J, Massetto B, Worth A, Kearney BP, Mathias A. Cytochrome P450 3A induction predicts P-glycoprotein induction; part 2: prediction of decreased substrate exposure after rifabutin or carbamazepine. Clin Pharmacol Ther. 2018;104:1191–1198. doi: 10.1002/cpt.1072. PubMed DOI PMC

Nies AT, Herrmann E, Brom M, Keppler D. Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1) Naunyn Schmiedebergs Arch Pharmacol. 2008;376:449–461. doi: 10.1007/s00210-007-0219-x. PubMed DOI

Nilles J, Weiss J, Sauter M, Haefeli WE, Ruez S, Theile D. Comprehensive in vitro analysis evaluating the variable drug–drug interaction risk of rifampicin compared to rifabutin. Arch Toxicol. 2023;97:2219–2230. doi: 10.1007/s00204-023-03531-2. PubMed DOI PMC

Nosol K, Romane K, Irobalieva RN, Alam A, Kowal J, Fujita N, Locher KP. Cryo-EM structures reveal distinct mechanisms of inhibition of the human multidrug transporter ABCB1. Proc Natl Acad Sci U S A. 2020;117:26245–26253. doi: 10.1073/pnas.2010264117. PubMed DOI PMC

Parvez MM, Kaisar N, Shin HJ, Jung JA, Shin JG. Inhibitory interaction potential of 22 antituberculosis drugs on organic anion and cation transporters of the SLC22A family. Antimicrob Agents Chemother. 2016;60:6558–6567. doi: 10.1128/AAC.01151-16. PubMed DOI PMC

Reitman ML, Chu X, Cai X, Yabut J, Venkatasubramanian R, Zajic S, Stone JA, Ding Y, Witter R, Gibson C, Roupe K, Evers R, Wagner JA, Stoch A. Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther. 2011;89:234–342. doi: 10.1038/clpt.2010.271. PubMed DOI

Smolinski MP, Urgaonkar S, Pitzonka L, Cutler M, Lee G, Suh KH, Lau JYN. Discovery of encequidar, first-in-class intestine specific P-glycoprotein inhibitor. J Med Chem. 2021;64:3677–3693. doi: 10.1021/acs.jmedchem.0c01826. PubMed DOI

Theile D, Schmidt TT, Haefeli WE, Weiss J. In-vitro evaluation of chronic alcohol effects on expression of drug-metabolizing and drug-transporting proteins. J Pharm Pharmacol. 2013;65:1518–1525. doi: 10.1111/jphp.12124. PubMed DOI

Theile D, Nilles J, Meid AD. Physiology-based pharmacokinetic modelling and experimental data suggest that rifabutin alters dolutegravir kinetics by both P-glycoprotein induction and concurrent inhibition. Br J Clin Pharmacol. 2023;89:2329–2331. doi: 10.1111/bcp.15740. PubMed DOI

Twentyman PR, Rhodes T, Rayner S. A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes. Eur J Cancer. 1994;30A:1360–1369. doi: 10.1016/0959-8049(94)90187-2. PubMed DOI

Vangone A, Schaarschmidt J, Koukos P, Geng C, Citro N, Trellet ME, Xue LC, Bonvin AMJJ. Large-scale prediction of binding affinity in protein-small ligand complexes: the PRODIGY-LIG web server. Bioinformatics. 2019;35:1585–1587. doi: 10.1093/bioinformatics/bty816. PubMed DOI

Weiss J, Weis N, Ketabi-Kiyanvash N, Storch CH, Haefeli WE. Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors. Eur J Pharmacol. 2008;579:104–109. doi: 10.1016/j.ejphar.2007.11.007. PubMed DOI

Weiss J, Herzog M, Haefeli WE. Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro. Eur J Pharmacol. 2011;660:298–304. doi: 10.1016/j.ejphar.2011.04.003. PubMed DOI

Weiss J, Theile D, Spalwisz A, Burhenne J, Riedel KD, Haefeli WE. Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells. Biochem Pharmacol. 2013;85:265–273. doi: 10.1016/j.bcp.2012.11.020. PubMed DOI

The "specific" P-glycoprotein inhibitor zosuquidar (LY335979) also weakly inhibits human organic cation transporters